Sterility testing is a quality control process that checks whether pharmaceutical products are free of viable microorganisms before they reach patients. It is required under current Good Manufacturing Practice (CGMP) regulations for the release of any finished product labeled as sterile, and it follows a standardized procedure outlined in USP chapter 71, which has been harmonized across the U.S., European, and Japanese pharmacopeias. The test itself involves placing samples of the product into nutrient-rich growth media and incubating them for 14 days to see if anything grows.
Which Products Require Sterility Testing
The range of products subject to sterility testing is broader than most people expect. It covers injectable drugs (including prefilled syringes), ophthalmic preparations, antibiotic solids for injection, oils and oily solutions, sterile ointments and creams, sterile aerosol products, surgical sutures, surgical dressings, and medical devices with pathways labeled sterile. Essentially, if a product enters the body through a route that bypasses the skin’s natural barrier, or if it contacts sterile tissue, it needs to pass this test before release.
Under CGMP rules enforced by the FDA, sterility testing is a mandatory part of finished product release. Compounding pharmacies operating under USP 797 guidelines may be exempt if they assign default storage times, but manufacturers producing commercial drug products cannot skip it.
Two Core Testing Methods
There are two accepted approaches: membrane filtration and direct inoculation. The choice between them depends on the nature of the product being tested.
In membrane filtration, the product is passed through a filter with pores small enough to trap any microorganisms. The filter is then placed into growth media. This method is generally preferred because it physically separates the drug from the growth environment, which matters when the product itself has antimicrobial properties that could kill organisms in the media and produce a false negative. Research comparing the two methods found that membrane filtration detected contamination in 29% more batches than direct inoculation when testing biological products.
Direct inoculation is simpler: samples of the product are added straight into containers of growth media. It remains necessary for products that cannot be filtered. Live viral biologics produced in cell culture, for example, were found to be the only product type among those studied that could reliably be filtered, meaning many biological products still require direct inoculation.
Growth Media and Incubation
Two types of growth media are used, each targeting different categories of organisms. Fluid thioglycollate medium (FTM) is incubated at a temperature that favors bacteria, particularly those that grow without oxygen. Soybean-casein digest medium (SCDM) is incubated at a lower temperature to support fungi and aerobic bacteria. Together, they cast a wide net across the types of contamination most likely to threaten a sterile product.
The standard incubation period is 14 days. During this time, technicians periodically examine the media for visible signs of microbial growth: cloudiness, sediment, surface films, or colonies. If the media remains clear after 14 days, the product passes.
How Many Samples Get Tested
The number of containers pulled from a batch for testing follows tables in USP 71 that scale with batch size and container volume. For liquid injectable products with a volume of 100 milliliters or more in batches larger than 500 containers, the minimum sample is either 20 containers or 2% of the total batch, whichever is lower. Smaller containers and smaller batches have their own requirements, but the principle is the same: enough units must be tested to provide reasonable confidence in the batch without destroying an impractical amount of product.
Method Suitability: Proving the Test Works
Before a sterility test can be used for a specific product, the laboratory must demonstrate that the product itself does not interfere with the test’s ability to detect contamination. This is called a method suitability test (sometimes called a bacteriostasis/fungistasis test). Technicians deliberately introduce known challenge organisms into the test system along with the product and confirm that those organisms still grow. If the product suppresses growth, say because it contains a preservative or antibiotic, the method needs to be adjusted, typically by increasing the rinse volume during membrane filtration to wash away residual antimicrobial activity.
What Happens When a Test Comes Back Positive
A positive sterility test, meaning visible microbial growth appears in the media, triggers a formal investigation. The FDA sets a high bar for dismissing a positive result: the contamination can only be attributed to laboratory error if the evidence is unequivocal. If the evidence is inconclusive, the batch must be rejected.
The investigation itself is extensive. It requires identifying the organism found (speciation), reviewing any deviations that occurred in the laboratory during testing, examining environmental monitoring data from the production area, reviewing personnel monitoring records, analyzing presterilization bioburden trends, auditing the batch production record, and reviewing the facility’s broader manufacturing history. The investigation must produce specific conclusions and identify corrective actions, supported by persuasive evidence pointing to the contamination’s origin.
Limitations of the 14-Day Test
An important caveat sits right in the text of USP 71 itself: “These Pharmacopeial procedures are not by themselves designed to ensure that a batch of product is sterile or has been sterilized.” Sterility testing is a sample-based, destructive test. You can only test a small fraction of a batch, so it is statistically possible for contamination to exist in untested units. True sterility assurance comes primarily from validating the sterilization process or the aseptic manufacturing procedures. The sterility test serves as a final verification layer, not the sole guarantee.
The 14-day incubation period also creates practical challenges. Finished products sit in quarantine for at least two weeks before they can be released, which complicates supply chains for time-sensitive medications.
Rapid Sterility Testing Alternatives
Newer technologies aim to shorten the 14-day window while maintaining equivalent sensitivity. One well-studied system uses automated detection of carbon dioxide produced by growing microorganisms in liquid culture media. As microbes metabolize nutrients, they release CO₂, which triggers a color change in a sensor built into the culture bottle. The system monitors bottles continuously, flagging positives as soon as they cross a detection threshold.
Performance studies have shown that these rapid systems detect challenge organisms faster than the traditional method. For example, one common test organism was detected in roughly 18.5 hours using the rapid system compared to about 23.7 hours in standard SCDM media. While both methods ultimately caught the contamination, the speed advantage is significant across a full incubation period. Rapid methods also simplify logistics by using a single incubation temperature for all organism types, rather than requiring two separate temperatures for FTM and SCDM.
These systems are recognized as viable alternatives for assessing sterility of injectable products, though manufacturers adopting them must validate the rapid method against the compendial procedure and meet regulatory expectations for equivalence.